Bookmark and Share

Compound Summary for: CID 9887712

Dapagliflozin

Also known as: 461432-26-8; BMS-512148; S1548_Selleck; CHEMBL429910; BMS-512148, Dapagliflozin; AKOS005145763; Forxiga (TN); D08897
Molecular Formula: C21H25ClO6   Molecular Weight: 408.8726   InChIKey: JVHXJTBJCFBINQ-ADAARDCZSA-N
Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014.    From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _